Warning: Use of undefined constant TDC_PATH_LEGACY - assumed 'TDC_PATH_LEGACY' (this will throw an Error in a future version of PHP) in /home/cannamjo/public_html/news/wp-content/plugins/td-composer/td-composer.php on line 107
Blueberries Medical to Collaborate with the International Research Center on Cannabis and Mental Health in New York for Product Formulation and the Development of Treatment-Focused Medical Education Programs - CannaMaps
Connect with us

Industry News

Blueberries Medical to Collaborate with the International Research Center on Cannabis and Mental Health in New York for Product Formulation and the Development of Treatment-Focused Medical Education Programs

Avatar

Published

on

default_cannabis_industry_cannamaps

TORONTO, April 15, 2019 (GLOBE NEWSWIRE) — Blueberries Medical Corp. (CSE: BBM) (OTCQB: BBRRF) (FRA: 1OA) (the “Company” or “Blueberries“) a Latin American licenced producer of medicinal cannabis and cannabis-derived products, has signed a definitive joint venture agreement (the “Agreement”) with the International Research Center on Cannabis and Mental Health (“IRCCMH” or the “Center”) for the development of medical education programs for physicians and patients in Latin America and product formulation.
IRCCMH is a leading research and academic organization in the cannabis sector with extensive experience in cannabis research and education, pharmacology, product formulation and the efficacy of cannabis-based treatments. Based in New York and aligned with the Silver School of Social Work at New York University, IRCCMH is comprised of renowned scientists, educators and clinicians and was created to bridge a gap between research and clinical practice. IRCCMH also creates education programs for physicians and patients and acts as advisor to several state-sponsored medical cannabis programs and has guided state regulators to create and implement cannabis programs in Pennsylvania, Delaware, New Jersey, Utah, California and other states. Founded by Jan Roberts, LCSW and Jahan Marcu, Ph.D, the Center’s founders and staff are regarded as thought leaders in the sector and have also been deeply involved with several other leading cannabis focused associations and are respected authors and speakers within the industry as further detailed below.“This collaboration agreement with IRCCMH provides an outstanding opportunity for Blueberries to leverage IRCCMH’s deep sector expertise to help educate physicians in Latin America and develop medical treatments for patients in the Latin American market and beyond. As cannabis regulation evolves globally, education and awareness are paramount to its adoption and the establishment of early mover advantages,” stated Dr. Patricio Stocker, Chief Executive Officer of the Company. “IRCCMH is a highly respected institution in the United States and their focus on education and research aligns with our goal of providing effective and responsible treatment to a broad spectrum of patients and customers globally. The agreement will emphasize education for prescribing doctors and patients and provide educational tools for all parties. This alliance will ensure that we are developing products and treatments that the medical community needs, with a streamlined process for reaching patients in these evolving markets.”IRCCMH will leverage its background and expertise to support the development of Blueberries’ commercial and educational initiatives. Together with IRCCMH, Blueberries is developing a treatment-focused medical education program designed to assist physicians in prescribing cannabis-based treatment plans to patients (the “Program”) in Latin America. A comprehensive patient and physician education program will be a cornerstone of Blueberries’ strategy for the introduction and adoption of cannabis-based treatments, positioning Blueberries as an early leader in the Latin American medicinal cannabis market.“IRCCMH is excited about our collaboration with Blueberries Medical and the opportunity to leverage our expertise in cannabis-based patient care, research and education in rapidly evolving global markets”, stated Jan Roberts, founder of IRCCMH stated, “This affiliation will help Blueberries position themselves in Latin America as a leader in medical cannabis treatment and will ensure that the research, education, and unique expertise of IRCCMH will impact a growing segment of medical treatment with cannabis in this region of the world.”This initiative will initially be rolled out through the company’s previously announced partnership with El Manantial Medical Centers in Bogota which will provide the platform, resources, patients and expertise needed to launch the Program and commercialize the formulations and products developed through the collaboration with the IRCCMH. Blueberries is further extending its patient & physician network currently, replicating the El Manantial Medical Center model with other physicians, institutions and medical associations.In addition to the development of best in class educational programs for the education of physicians and patients in Latin America, access to IRCCMH´s team of specialists with deep expertise in medical cannabis will facilitate faster product development and generate the appropriate formulations and product standardization to accelerate the commercialization of the Company’s medicinal cannabis products, initially through El Manantial Medical Center’s rapidly growing patient base and the Company’s other strategic arrangements.About IRCCMH & IRCCMH Founders
Based in New York and aligned with the Silver School of Social Work at NYU and building upon years of expertise working with cannabis and mental health in the United States, IRCCMH was created to bridge a gap between research and clinical practice. IRCCMH was co-founded by Jan Roberts and Dr. Jahan Marcu in 2017 to provide quality research and education to the medical cannabis community.  IRCCMH is a community-based institute in New York City that collaborates with universities, researchers, foundations, state institutions, and other organizations to leverage the best talent in the field. The Institute works to build educational seminars, expand research with universities, and provide consultation for healthcare professionals and regulatory organizations in order to improve patient care. Through its numerous projects, Marcu and Roberts have been instrumental in creating dialogues in areas of cannabis education and investigation that hadn’t been previously addressed. 
For more information visit www.irccmh.org/about-irccmh.Jan Roberts, LCSW: CEO & Director of Translational Research
Jan Roberts is a co-founder for IRCCMH and serves as CEO and Director of Translational Research. Ms. Roberts is a Licensed Clinical Social Worker who owns and operates one of the largest collaborative care practices in the mid-Atlantic region – Partners in Health and Wellbeing. Ms. Roberts is a clinician and an entrepreneur with an activist spirit who has extensive experience running both non-profit and for-profit healthcare organizations.
Ms. Roberts teaches at NYU Silver School of Social Work and is currently working on a funded study of Mental Health Clinicians and Knowledge and Attitudes on Cannabis.  She is also Guest-Editor for a Special Issue on Cannabis and Mental Health for the Clinical Social Work Journal (CSWJ). Ms. Roberts’ current work is focused on the clinical application of cannabis in mental health settings and focusing on maladaptive coping strategies rather than a substance-based approach to treating addictions. As a result, Ms. Roberts is especially interested in educating fellow mental health clinicians on the most recent research findings to address stigma and lack of knowledge related to cannabis, the endocannabinoid system and mental health outcomes.Jahan Marcu, Ph.D.: COO & Director of Experimental Pharmacology and Behavioral Research
Jahan Marcu, Ph.D., is a co-founder for IRCCMH. Dr. Marcu is the former Chief Science Officer at Americans for Safe Access (a medical cannabis advocacy non-profit) and former Director of the Patient Focused Certification program, which is a health and safety oversight program that assesses regulatory compliance at cannabis operations.
He is co-founder and past-chairman of the CANN subdivision of the Chemical Health and Safety Division (DCHAS) of the American Chemical Society. His is also on the Board of Directors of the International Association for Cannabinoids as Medicine.  He has a background in analytical chemistry and molecular pharmacology, and received his Ph.D. for contributions in characterizing the structure and function of the cannabinoid receptors. He is an author of the American Herbal Pharmacopeia’s Cannabis Monograph and serves on multiple expert government, trade association committees and scientific organizations.Dr. Marcu has helped create medical cannabis educational training for clinicians and for workers in the medical cannabis industry, and has been invited to speak at many international conferences and universities, including the University of Leiden, Temple University School of Medicine, Princeton Hospital, and Yale University. Dr. Marcu is also a court qualified expert witness on cannabis and synthetic cannabinoids.Dr. Marcu is a recipient of the Billy Martin research award from the International Cannabinoid Research Society.About Blueberries Medical Corp.
Blueberries is a Latin American licensed producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá Savannah of central Colombia and operations currently being established in Argentina. The Company is led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis in Colombia. Blueberries’ combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products.
Additional information about the Company is available at www.blueberriesmed.com. For more information, please contact:Camilo Villalba, Chief Operating Officer
Tel: +57.313.483.0131
Email: cvillalba@blueberriesmed.com
Jessika Angarita, Pacta Relations
angarita@pactarelations.com
Tel: +1 (305) 877 4710
Cautionary Note Regarding Forward-Looking InformationThis news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward looking statements“) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, to: expectations relating to the potential benefits of the Agreement and the Company’s partnership with the Center, expectations regarding the development and commercialization of the Company’s products, and future growth plans.These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Colombian and international medical cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Colombia or internationally; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Original story can be found at: http://www.globenewswire.com/news-release/2019/04/15/1803902/0/en/Blueberries-Medical-to-Collaborate-with-the-International-Research-Center-on-Cannabis-and-Mental-Health-in-New-York-for-Product-Formulation-and-the-Development-of-Treatment-Focused.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

500 Patients in 100 Days and Investing in Australian Companies: Compass Lifestyle Clinics Looks towards the future of Medicinal Cannabis

Avatar

Published

on

default_cannabis_industry_cannamaps

SYDNEY, Australia, Aug. 27, 2019 (GLOBE NEWSWIRE) — Today, Starbuds International (“the Company”), parent company to Compass Lifestyle clinics (“Compass”), is pleased to provide an update on its activities since launching its first medical clinic in Sydney Australia in May.
500 patients in 100 daysWithin 100 days of opening, Compass Lifestyle Clinics has seen over 500 patients and helped provide safe access to medicinal cannabis under the watch of the Therapeutic Goods Association (“TGA”). The company is now looking to expand its capacity to serve patients across Australia.Dr. Teresa Towpik wins Doctor of the YearAt the 2019 Cannabis Industry Awards for Australia, the honours of Doctor of the Year were taken home by Compass Chief Medical Officer, Dr. Teresa Towpik. The award comes as further validation for the work Dr. Towpik has done to bring cannabis into the mainstream as a medicinal cannabis advocate in addition to her tireless work both educating doctors around prescribing as well as serving patients.Investment in Australian Cannabis Grower Medigrowth AustraliaThe Company has also secured a minority investment in Australian Medicinal cannabis late stage applicant and cultivation company Medigrowth Australia. The investment further strengthens Compass’ position in the supply chain, combining patient-centric advocacy & GP education with a leading Australian medicinal cannabis grower and extractor.
             
“Our strategic partnership with Compass consolidates our commitment to patient access and advocacy. We look forward to working with the highly respected team at Compass to educate, inspire and innovate.” says Adam Guskich, Co founder of Medigrowth Australia. “Our combined resources will prove instrumental in providing access to pure, safe, trusted and affordable Australian grown pharma grade medicinal cannabis for Australian patients.”
Along with this announcement, Brianna Martyn, Co-Founder of Starbuds International, has been appointed to the Strategic Advisory Board“Australia has welcomed us with open arms”, says Dave Martyn, President of Compass. “When we did our research, we could see Australians were underserved when it came to safe access to medicinal cannabis. At the same time, from an economic standpoint, we’ve seen what an incredible job creator the cannabis sector has been in Canada. We’ve been fortunate to partner with some of the top cannabis leaders in Australia to play a part in ensuring safe patient access while also helping to grow the industry at large.”The news at a time when medical cannabis acceptance is rapidly growing. With monthly approvals increasing recent news around the removal of red tape surrounding cannabis companies, Compass is poised to expand it’s presence in Australia as it looks towards multi-clinic expansion as well as further investment opportunities.   Those interested in learning more about Compass Lifestyle Clinics can do so at https://compassclinics.com.au or in Canada at https://compasscannabis.ca.About Compass Cannabis ClinicsCompass Cannabis Clinic is a medical cannabis service provider whose core business is focused on providing educational and consultative services to those looking for access to medicinal cannabis. Compass works with a number of Licenced Producers to ensure the right product for the patient while eliminating product bias for prescribers. With several clinics operating in Canada and over 13,000 patients served, Compass has now expanded into Australia with its first clinic in Sydney. Compass Lifestyle Clinics, located in Sydney, with plans for rapid expansion. Compass also operates recreationally in Canada as Starbuds Canada.For further information contactDaniel Winer
Marketing Director
daniel.winer@compassclinics.com.au 
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “anticipate”, “achieve”, “could”, “believe”, “plan”, “intend”, “objective”, “continuous”, “ongoing”, “estimate”, “outlook”, “expect”, “may”, “will”, “project”, “should” or similar words, including negatives thereof, suggesting future outcomes. Management of the Company believes the expectations reflected in such forward-looking statements are reasonable as of the date hereof but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon. Various material factors and assumptions are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements. Those material factors and assumptions are based on information currently available to the Company, including data from publicly available governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of the retail cannabis industry which the Company believes to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. While the Company is not aware of any misstatement regarding any industry or government data presented herein, the retail cannabis industry involves risks and uncertainties and is subject to change based on various factors.
Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company’s actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements.Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e52045f5-e820-43b1-9d91-9f5d3e5e9622

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/27/1907468/0/en/500-Patients-in-100-Days-and-Investing-in-Australian-Companies-Compass-Lifestyle-Clinics-Looks-towards-the-future-of-Medicinal-Cannabis.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

Radient Technologies Inc. Releases First Quarter 2020 Financial Results and Provides Corporate Update

Avatar

Published

on

default_cannabis_industry_cannamaps

EDMONTON, Alberta, Aug. 27, 2019 (GLOBE NEWSWIRE) — Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a global innovator in the industrial scale extraction and downstream processing of premium grade cannabis and hemp derivatives, has released its financial results for the first quarter of its fiscal year 2020, ending June 30, 2019. The financial statements and Management’s Discussion & Analysis are available under the Company’s profile at www.SEDAR.com.
Financial Highlights:Strong cash position:As at June 30th, 2019 the Company had maintained a cash position of CAD $23.5 million.Large inventory for increased future revenue generation:As part of the Company’s business model, which will allow it to benefit from advantages related to cost, scale, and yield provided by its proprietary extraction and processing platform, Radient has secured a large inventory of cannabis biomass (valued at CAD $21.7 million), which will be processed at its Edmonton I manufacturing facility into extracts for sale to Canadian Licensed Producers. This inventory is mainly the result of Radient’s purchase of CAD $19.5 million worth of dried cannabis biomass from Canadian Licensed Producers, including Aurora Cannabis Inc. (“Aurora”), which the Company initially announced on July 8, 2019.
 
Radient has secured buyers for the majority of these extracts. Revenues earned from the sale of these extracts are expected to be in excess of the value of the current total inventory of dried cannabis biomass (CAD $21.7 million), and the Company expects this will have a meaningful positive impact on its earnings reported across fiscal Q2 2020 and/or fiscal Q3 2020. Due to various supply chain factors including shipment of biomass, product analysis and delivery of final product, the Company expects the majority of this revenue will be reported in fiscal Q3 2020.
Corporate Update:Successful scale up of throughput at Edmonton I facility:Since the commencement of extraction and processing activities at its Edmonton I facility (“Edmonton I”) in March 2019, Radient has begun to significantly scale up throughput batch sizes of cannabis biomass by multiples of 5x – 10x, in line with the Company’s expectations. Edmonton I has a throughput capacity of 56,0000 kg/ year of cannabis at full capacity.Recovery and quality of cannabinoids has exceeded expectations:Radient is pleased to report results from the scale-up at Edmonton I have proven:Cannabinoid recovery (yield) from biomass is consistently above 90%, and up to 99%.Cannabis extracts have maintained product stability, including negligible cannabinoid degradation.  Hemp processing line on track for completion:Radient’s Edmonton II Facility (“Edmonton II”), dedicated to the extraction and downstream processing of CBD from hemp, is on track for completion at the end of calendar 2019. Upon completion, Edmonton II is expected to have an annual throughput capacity of 420,000 kg/ year of hemp.Expansion into Germany:Radient’s Germany facility (‘Germany”) is expected to begin initial commissioning in the second half of calendar 2020, scaling up to its full capacity of 280,000 kg of cannabis and 2.8 million kg/ year of hemp thereafter. Please refer to the subsection titled “Germany” under “Cannabis Activities” in the MD&A for further details.Expanded throughput capacity in Canada:Radient’s Edmonton III facility (“Edmonton III”), currently under construction, is expected to be commissioned in the second half of calendar 2020, scaling up to its full capacity of 280,000 kg of cannabis and 2.8 million kg/ year of hemp thereafter.
 
Upon completion of its Edmonton II, Edmonton III and Germany facilities, Radient will have a combined total annual throughput capacity of more than 600,000 kg/year of cannabis and more than 6 million kg/ year of hemp across Canada and Germany.EU GMP compliance:Radient is building both its Edmonton III and Germany facilities to be EU GMP compliant.Post-Reporting:Improved working capital via Amended Loan Facility Agreement:The Company announced the amendment of its original loan facility with Moskowitz Capital Mortgage Fund on August 26, 2019, which increased the amount of the loan from CAD $5.5 million to $8.5 million, and extended the maturity date of the loan from November 1, 2020 to November 1, 2021.Consumer product manufacturing:In anticipation of upcoming changes to the Cannabis Act, which will make the production and sale of edible cannabis, cannabis extracts and cannabis topicals legal in Canada as of October 2019, Radient has been developing a range of compounds and formulations to meet anticipated demand of its clients. In particular, Radient has been focusing on formulation development for various vaping products, edible cannabis products, cannabis extracts and cannabis topicals that its clients will be introducing into the Canadian marketplace. The Company has developed vaping liquid formulations for commercialization and is preparing its manufacturing operations for the production of vaping liquids and cartridge filling, and expects the production of vaping liquid will begin in fiscal Q3 2020. Management Commentary:“This is a key inflection point for Radient,” Denis Taschuk, President & CEO of Radient commented. “During fiscal Q1 2020 we proved our processing and manufacturing capabilities with respect to cannabis, and subsequently acquired a large inventory of cannabis biomass in order to develop white label cannabinoid derivatives for sale to Canadian LPs. We see this as a significant turning point for Radient as a revenue generating company, and we expect this will be clearly reflected in our Q2 2020 and/ or Q3 2020 financials.”  About Radient 
Radient Technologies provides industrial-scale manufacturing solutions for premium natural ingredients and products. Utilizing its patented MAP™ extraction technology, Radient delivers superior customer outcomes in terms of ingredient purity, yield, and cost, serving global market leaders in industries such as foods & beverages, nutraceuticals, pharmaceuticals, cosmetics, and personal care. Since 2016, Radient has expanded its offerings to enter the cannabinoids market, using its proprietary platform to provide premium ingredients including those that contain a broad range of cannabinoid and terpene profiles. Please visit www.radientinc.com for more information.
SOURCE: Radient Technologies Inc.Investors please contact: William (Bill) Wasson, Senior VP of Capital Markets and Investor Relations: wwasson@radientinc.comMedia/press please contact: Caitlin Cheadle, Director of Communications: ccheadle@radientinc.comForward Looking Information:
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the growth of the Company’s business operations; the construction of the Company’s facilities; the Company’s future revenues and timing of such revenues; the Company’s future products; the Company’s ability to sell its products and attract new customers; the expected throughput capacities at its facilities as set out in the “Corporate Update” section above;  the future recovery and quality of the Company’s extracts; the Company’s ability to expand its business internationally; the Company’s ability to grow its business in the cannabis sector and the Company’s future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/27/1907438/0/en/Radient-Technologies-Inc-Releases-First-Quarter-2020-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

Cannabis World Congress & Business Exposition Brings Industry’s Top Conference Program to Los Angeles

Avatar

Published

on

default_cannabis_industry_cannamaps

NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) — via CannabisNewsWire – Leading Edge Expositions, a company specializing in B2B trade show production, is proud to announce further details of the upcoming Cannabis World Congress & Business Exposition (CWCBExpo) in Los Angeles, California. It will run from September 26 – 28, 2019, at the Los Angeles Convention Center.
The expo has garnered a number of high-powered sponsors. Their diamond sponsor, Freed, is a prominent CBD company known for promoting healthy living. Other big sponsors include Marcum LLP, an accounting group; Zuber Lawler, a global law firm; and CCELL, known for its disruptive vaping technology. These and other leading companies in the cannabis space have come together to help make CWCBExpo a highly valuable and memorable occasion.Event organizers have also ensured the conference schedule will be packed with interesting and informative speeches, workshops and networking opportunities for all guests in attendance. The keynote address, scheduled for September 26, will be given by Steve White, CEO of Harvest, Inc. He will discuss social justice in the cannabis industry.Other speeches on the agenda will cover the cannabis industry from a myriad of angles, including the medical field, business, law and growers. For those interested in business and law, there will be additional workshops detailing how to manage the blossoming cannabis industry and what laws and regulations business owners should be aware of while their businesses grow.Finally, to provide greater ROI to every guest, speaker and sponsor attending, the expo will include multiple networking events designed to foster new business relationships to capitalize on the fast-growing market. On the evenings of September 26 and 27, CWCBExpo will offer networking opportunities for guests to unwind while making useful connections. Attendees are also encouraged to get involved in the various workshops to make important connections.Demand for CWCBExpo is sure to grow even further as the event draws closer. Attendees who purchase their tickets now will benefit from discounted pricing. To register for the upcoming Cannabis World Congress & Business Expo in Los Angeles, visit: https://www.cwcbexpo.com/attend-registration-los-angeles/About Cannabis World Congress & Business Expositions (CWCBExpo)
CWCBExpos are the premier business-to-business events for the legalized cannabis industry and are held 3 times per year in the largest financial, business, and media markets—New York, Los Angeles and Boston. Connect on Twitter, Facebook, Instagram, and LinkedIn: @cwcbexpo.
General Inquiries:
Leading Edge Expositions, LLC
Paramus, New Jersey
201.580.2050 Office
Media Contact:
CannabisNewsWire (CNW) 
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
editor@CannabisNewsWire.com

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/27/1907192/0/en/Cannabis-World-Congress-Business-Exposition-Brings-Industry-s-Top-Conference-Program-to-Los-Angeles.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Trending